Bcl2 expression and its correlation with neuroendocrine differentiation in colon carcinomas.
OBJECTIVE
In this study we investigated the association between BCL2 expression and neuroendocrine differentiation in tubular adenomas and colon carcinomas. We also evaluated the prognostic significance of BCL2 expression and neuroendocrine differentiation in the carcinoma group.


METHODS
Forty-eight colon carcinomas and twelve tubular adenomas were stained immunohistochemically with BCL2 and chromogranin A (CgA). Staining patterns were scored semiquantitatively and correlated with tumor type, tumor grade, Dukes stage, and survival time.


RESULTS
BCL2 expression was detected in 7 of 12 (58.3%) adenomas and 37 of 48 (77.0%) carcinomas. In normal mucosa we observed positive staining only in the basal portions of the crypts. However, diffuse positivity was observed in the adenomas and carcinomas. Carcinomas had significantly higher BCL2 scores than the normal group, but we did not observe any significant differences either between the adenoma and carcinoma group or between the adenoma and normal group. BCL2 scores were higher in stage B than in stage C tumors, and in adenocarcinomas than in mucinous carcinomas. CgA positivity was observed in 24 of 48 (50%) carcinomas. It was not detected in adenomas. We did not find a significant correlation between CgA expression and any of the clinicopathological parameters.


CONCLUSIONS
On consecutive sections BCL2 and CgA positivity closely paralleled each other and a significant positive correlation was observed between CgA and BCL2 expression. These findings suggest a close association between BCL2 expression and neuroendocrine differentiation and indicate that BCL2 may be involved in neuroendocrine differentiation in addition to its role in protecting cells from apoptosis.
Atasoy
Pinar
P
Department of Pathology, Kirikkale University School of Medicine, Ankara, Turkey. cetinatasoy@hotmail.com
Bozdoğan
Onder
O
Oztürk
Sibel
S
Ensari
Arzu
A
D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000473:pathology; D000236:Adenoma / Q000737:chemistry / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D018278:Carcinoma, Neuroendocrine / Q000737:chemistry* / Q000473:pathology*; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis*; D003110:Colonic Neoplasms / Q000737:chemistry* / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D019253:Proto-Oncogene Proteins c-bcl-2